Abstract: The disclosure provides a method for synthesizing free base foams of (2R,6R)-hydroxynorketamine (HNK) and (2S,6S)-hydroxynorketamine. In an embodiment synthesis of (2R,6R)-hydroxynorketamine (HNK) includes preparation of (R)-norketamine via chiral resolution from racemic norketamine via a chiral resolution with L-pyroglutamic acid. The disclosure also provided crystal foams of the corresponding (2R,6R)-hydroxynorketamine (HNK) and (2S,6S)-hydroxynorketamine hydrochloride salts.

Abstract: The present invention relates to novel alpha5 subunit-selective negative allosteric modulators of GABAA receptors that have been deuterated to improve their medicinal properties by prolonging their half-lives, rendering them useful as fast-acting pharmaceutical treatments for depression related disorders.

Abstract: Compounds and methods of using the same for treating diseases and conditions including a depressive disorder, an anxiety disorder, drug addiction, schizophrenia, Alzheimer's dementia, amyotrophic lateral sclerosis, complex regional pain syndrome (CRPS), chronic pain, neuropathic pain, anhedonia, and fatigue are provided.

Abstract: The disclosure provides a method for synthesizing free base forms of (2R,6R)-hydroxynorketamine (HNK) and (2S,6S)-hydroxynorketamine. In an embodiment synthesis of (2R,6R)-hydroxynorketam-ine (HNK) includes preparation of (R)-norket-amine via chiral resolution from racemic norketamine via a chiral resolution with L-pyro-glutamic acid. The disclosure also provided crystal forms of the corresponding (2R,6R)-hydroxynorketamine (HNK) and (2S,6S)-hy-droxynorketamine hydrochloride salts.

Abstract: The disclosure provides a method for synthesizing free base forms of (2R,6R)-hydroxynorketamine (HNK) and (2S,6S)-hydroxynorketamine. In an embodiment synthesis of (2R,6R)-hydroxynorketamine (HNK) includes preparation of (R)-norketamine via chiral resolution from racemic norketamine via a chiral resolution with L-pyroglutamic acid. The disclosure also provided crystal forms of the corresponding (2R,6R)-hydroxynorketamine (HNK) and (2S,6S)-hydroxynorketamine hydrochloride salts.

Abstract: The present invention relates to novel alpha5 subunit-selective negative allosteric modulators of GABAA receptors that have been deuterated to improve their medicinal properties by prolonging their half-lives, rendering them useful as fast-acting pharmaceutical treatments for depression related disorders.

Abstract: The present invention relates to novel alpha5 subunit-selective negative allosteric modulators of GABAA receptors that have been deuterated to improve their medicinal properties by prolonging their half-lives, rendering them useful as fast-acting pharmaceutical treatments for depression related disorders.

Abstract: A dunnage device is disclosed. The dunnage device includes a mounting plate to secure the device to a trailer. The dunnage device is supported in a raised position by a first and second support plate. The dunnage device is configured to bear a load in the raised position by a load supporting plate connected to the first and second support plates. The dunnage device is able to transition between the raised position to a lowered position with a reduced profile. The translation of the dunnage device occurs by one or more pivotable connections.

Abstract: The disclosure provides a method for synthesizing free base forms of (2R,6R)-hydroxynorketamine (HNK) and (2S,6S)-hydroxynorketamine. In an embodiment synthesis of (2R,6R)-hydroxynorketamine (HNK) includes preparation of (R)-norketamine via chiral resolution from racemic norketamine via a chiral resolution with L-pyroglutamic acid. The disclosure also provided crystal forms of the corresponding (2R,6R)-hydroxynorketamine (HNK) and (2S,6S)-hydroxynorketamine hydrochloride salts.

Abstract: The disclosure provides a method for synthesizing free base forms of (2R,6R)-hydroxynorketamine (HNK) and (2S,6S)-hydroxynorketamine. In an embodiment synthesis of (2R,6R)-hydroxynorketamine (HNK) includes preparation of (R)-norketamine via chiral resolution from racemic norketamine via a chiral resolution with L-pyroglutamic acid. The disclosure also provided crystal forms of the corresponding (2R,6R)-hydroxynorketamine (HNK) and (2S,6S)-hydroxynorketamine hydrochloride salts.

Abstract: The present invention relates to novel alpha5 subunit-selective negative allosteric modulators of GABAA receptors that have been deuterated to improve their medicinal properties by prolonging their half-lives, rendering them useful as fast-acting pharmaceutical treatments for depression related disorders.

Abstract: The disclosure provides a method for synthesizing free base forms of (2R,6R)-hydroxynorketamine (HNK) and (2S,6S)-hydroxynorketamine. In an embodiment synthesis of (2R,6R)-hydroxynorketamine (HNK) includes preparation of (R)-norketamine via chiral resolution from racemic norketamine via a chiral resolution with L-pyroglutamic acid. The disclosure also provided crystal forms of the corresponding (2R,6R)-hydroxynorketamine (HNK) and (2S,6S)-hydroxynorketamine hydrochloride salts.

Abstract: Disclosed is a method of treating Psychotic Depression, Suicidal Ideation, Disruptive Mood Dysregulation Disorder, Persistent Depressive Disorder (Dysthymia), Premenstrual Dysphoric Disorder, Substance/Medication-Induced Depressive Disorder, Depressive Disorder Due to Another Medical Condition, Other Specified Depressive Disorder, Unspecified Depressive Disorder, Separation Anxiety Disorder, Selective Mutism, Specific Phobia, Social Anxiety Disorder (Social Phobia), Panic Disorder, Panic Attack (Specifier), Agoraphobia, Generalized Anxiety Disorder, Substance/Medication-Induced Anxiety Disorder, Anxiety Disorder Due to Another Medical, Other Specified Anxiety Disorder, Unspecified Anxiety Disorder, or fatigue the method including administering a pharmaceutical composition containing an effective amount of an active agent, wherein the active agent is purified (2R,6R)-hydroxynorketamine, purified (2S,6S)-hydroxynorketamine, or a combination thereof, or a pharmaceutically acceptable salt thereof, together with a

Abstract: A motorized car wash device having a hand held washer with a telescopic handle for reaching up to ten feet, as well as a sealed control tube featuring a plurality of control buttons. The tube is connected to a head by a double ear axle joint. The head includes a soap reservoir. A soap pump and soap jets are disposed on a bottom side of the head. Variable speed choices are available for multi-speed motorized direct drive of a receiver selectively holding a plurality of spinning brushes and pads. Pivoting lights provide use of the device in low light conditions. Each of the pump, the jets, the multi-speed motor and the lights in operational communication with the control buttons and batteries.

Abstract: The present invention relates to crystalline forms of ECO-4601 and the processes for providing them. The invention further relates to pharmaceutical compositions comprising the crystalline forms and to methods of use of the crystalline forms as pharmaceuticals.

Abstract: An inflatable horseshoe support pad for preventing and treating laminitis and navicular syndrome, among other maladies, including a body member and an inflatable bladder. The inflatable horseshoe pad is mounted between the hoof of the horse and the horseshoe with the bladder mounted on the upper surface of the body member near the heel portion so that it engages the frog of a horse's hoof when installed on the hoof. The support pad is mounted under the bladder. A frog pad can also be mounted under the support pad.

Abstract: An inflatable horseshoe support pad for treating laminitis and navicular syndrome, among other maladies, including a body member with a toe portion, a heel portion, an upper, hoof-facing surface and a lower, ground-facing surface. An inflatable bladder is disposed on the upper surface of the body member near the heel portion so that it engages the frog of a horse's hoof when installed on the hoof.

Abstract: A system is described in which central images are stored at a central server and local images, corresponding to the central images, are stored at one or more local terminals. A local image can be modified to generate a modified local image and modification data describing the modifications made sent to the central server so that the central server can create a modified central image that corresponds to the modified local image without requiring the image as modified to be transmitted from the local terminal to the central server. Similarly, modifications can be made to a central image and modification data describing the modifications made sent to a local terminal so that the local terminal can create a modified local image corresponding to the modified central image without requiring the modified central image to be sent from the central server to the local terminal.

Abstract: The gp4l and Dda helicases were found to significantly enhance the dissociation rate of streptavidin from biotin-labeled oligonucleotides in an ATP dependent reaction, demonstrating that these enzymes are capable of imparting a significant force on a molecule blocking their path. The present invention describes an assay for studying enzymatic activity of a helicase using the rate of dissociation of streptavidin from biotinylated oligonucleotides.